BIIB

BIIB

USD

Biogen Inc. Common Stock

$124.990-4.560 (-3.520%)

السعر في الوقت الحقيقي

Healthcare
Drug Manufacturers - General
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$129.550

الأعلى

$129.580

الأدنى

$124.680

الحجم

1.14M

أساسيات الشركة

القيمة السوقية

18.3B

الصناعة

Drug Manufacturers - General

البلد

United States

إحصاءات التداول

متوسط الحجم

1.48M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $110.04الحالي $124.990الأعلى $236.48

أخبار ذات صلة

GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved

عرض المزيد
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
GlobeNewswire

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA®

عرض المزيد
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Analyst Upgrades

RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target

RBC Capital analyst Brian Abrahams reiterates Biogen with a Outperform and maintains $213 price target.

عرض المزيد
RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Biogen with a Buy and maintains $187 price target.

عرض المزيد
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target
GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA

عرض المزيد
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Analyst Upgrades

Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target

Piper Sandler analyst David Amsellem reiterates Biogen with a Neutral and maintains $115 price target.

Analyst Upgrades

Wedbush Reiterates Neutral on Biogen, Maintains $121 Price Target

Wedbush analyst Laura Chico reiterates Biogen with a Neutral and maintains $121 price target.

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.